• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

治疗前F-FAMT PET/CT代谢肿瘤体积在非小细胞肺癌中的预后价值。

Prognostic value of metabolic tumor volume of pretreatment F-FAMT PET/CT in non-small cell lung Cancer.

作者信息

Kumasaka Soma, Nakajima Takahito, Arisaka Yukiko, Tokue Azusa, Achmad Arifudin, Fukushima Yasuhiro, Shimizu Kimihiro, Kaira Kyoichi, Higuchi Tetsuya, Tsushima Yoshito

机构信息

Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Showa-machi 3-39-22, Maebashi, Gunma, 371-8511, Japan.

Department of Nuclear Medicine and Molecular Imaging Faculty of Medicine, Universitas Padjadjaran Jalan Professor Eyckman No.38, Bandung, Jawa Barat, 40161, Indonesia.

出版信息

BMC Med Imaging. 2018 Nov 26;18(1):46. doi: 10.1186/s12880-018-0292-2.

DOI:10.1186/s12880-018-0292-2
PMID:30477476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6258278/
Abstract

BACKGROUND

This study aimed to determine the prognostic value of positron emission tomography (PET) metabolic parameters-namely metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion retention (TLR)-on fluorine-18 (F) fluorodeoxyglucose (FDG) and L- [3-F]-α-methyltyrosine (F-FAMT) PET/CT in patients with non-small-cell lung cancer (NSCLC).

METHODS

The study group comprised 112 NSCLC patients who underwent F-FDG and F-FAMT PET/CT prior to any therapy. The MTV, TLG, TLR, and maximum standardized uptake value (SUV) of the primary tumors were determined. Automatic MTV measurement was performed using PET volume computer assisted reading software. (GE Healthcare). Cox proportional hazards models were built to assess the prognostic value of MTV, TLG (for F-FDG), TLR (for F-FAMT), SUV, T stage, N stage, M stage, clinical stage, age, sex, tumor histological subtype, and treatment method (surgery or other therapy) on overall survival (OS).

RESULTS

Higher TNM, higher clinical stage, inoperable status, and higher values for all PET parameters (both F-FAMT and F-FDG PET) were significantly associated (P < 0.05) with shorter OS. Multivariate analysis revealed that a higher MTV of F-FAMT (hazard ratio [HR]: 2.88, CI: 1.63-5.09, P < 0.01) and advanced clinical stage (HR: 5.36, CI: 1.88-15.34, P < 0.01) were significant predictors of shorter OS.

CONCLUSIONS

MTV of F-FAMT is of prognostic value for OS in NSCLC cases and can help guide decision-making during patient management.

摘要

背景

本研究旨在确定正电子发射断层扫描（PET）代谢参数，即代谢肿瘤体积（MTV）、总病灶糖酵解（TLG）和总病灶滞留（TLR），对非小细胞肺癌（NSCLC）患者进行氟-18（F）氟脱氧葡萄糖（FDG）和L-[3-F]-α-甲基酪氨酸（F-FAMT）PET/CT检查的预后价值。

方法

研究组包括112例NSCLC患者，这些患者在接受任何治疗之前均接受了F-FDG和F-FAMT PET/CT检查。测定了原发肿瘤的MTV、TLG、TLR和最大标准化摄取值（SUV）。使用PET体积计算机辅助阅读软件（GE医疗）进行自动MTV测量。构建Cox比例风险模型，以评估MTV、TLG（针对F-FDG）、TLR（针对F-FAMT）、SUV、T分期、N分期、M分期、临床分期、年龄、性别、肿瘤组织学亚型和治疗方法（手术或其他治疗）对总生存期（OS）的预后价值。

结果

更高的TNM分期、更高的临床分期、无法手术的状态以及所有PET参数（F-FAMT和F-FDG PET）的更高值均与较短的OS显著相关（P < 0.05）。多变量分析显示，F-FAMT的更高MTV（风险比[HR]：2.88，置信区间[CI]：1.63 - 5.09，P < 0.01）和晚期临床分期（HR：5.36，CI：1.88 - 15.34，P < 0.01）是较短OS的显著预测因素。

结论

F-FAMT的MTV对NSCLC病例的OS具有预后价值，并有助于在患者管理期间指导决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/8465eecabc5b/12880_2018_292_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/86c6b05d0d03/12880_2018_292_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/c2d7f9f94ff2/12880_2018_292_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/b1e470de7748/12880_2018_292_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/862e97829ecc/12880_2018_292_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/8465eecabc5b/12880_2018_292_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/86c6b05d0d03/12880_2018_292_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/c2d7f9f94ff2/12880_2018_292_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/b1e470de7748/12880_2018_292_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/862e97829ecc/12880_2018_292_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e514/6258278/8465eecabc5b/12880_2018_292_Fig5_HTML.jpg

相似文献

1
Prognostic value of metabolic tumor volume of pretreatment F-FAMT PET/CT in non-small cell lung Cancer.治疗前F-FAMT PET/CT代谢肿瘤体积在非小细胞肺癌中的预后价值。
BMC Med Imaging. 2018 Nov 26;18(1):46. doi: 10.1186/s12880-018-0292-2.
2
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.（18）F-FDG PET 代谢肿瘤负荷对非小细胞肺癌手术患者的预后价值。
Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.
3
Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.治疗前 FDG PET/CT 全身总病变糖酵解对非小细胞肺癌的预后价值。
Radiology. 2012 Aug;264(2):559-66. doi: 10.1148/radiol.12111148. Epub 2012 Jun 12.
4
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.代谢肿瘤负荷 18F-FDG PET 在非手术治疗的非小细胞肺癌患者中的预后价值。
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.
5
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.基于基线 18F-FDG PET/CT 的各种代谢参数在接受铂类化疗的非小细胞肺癌患者中的作用作为预后标志物。
Clin Nucl Med. 2018 Jan;43(1):e8-e17. doi: 10.1097/RLU.0000000000001886.
6
Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.局部晚期非小细胞肺癌患者风险分层的 FDG PET/CT 最佳容积学参数：来自 ACRIN 6668/RTOG 0235 试验的结果。
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):1969-1983. doi: 10.1007/s00259-017-3753-x. Epub 2017 Jul 8.
7
Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.（18）F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的基于体积的参数可改善手术切除后早期非小细胞肺癌的预后预测。
Ann Surg. 2013 Feb;257(2):364-70. doi: 10.1097/SLA.0b013e318262a6ec.
8
Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.循环肿瘤细胞与 18F-FDG PET/CT 联合应用于非小细胞肺癌患者的精准诊断。
Cancer Med. 2024 Sep;13(18):e70216. doi: 10.1002/cam4.70216.
9
Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.采用 FDG PET/CT 测量的容积参数在接受立体定向体部放射治疗的 I 期 NSCLC 患者中的应用：预后价值。
Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.
10
18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.18F-FDG PET/CT 和未经治疗的非小细胞肺癌患者的循环肿瘤细胞。
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3250-3259. doi: 10.1007/s00259-021-05260-z. Epub 2021 Feb 25.

引用本文的文献

1
Prognostic value of pre-treatment metabolic tumor volume on [S‑methyl‑C]‑L‑methionine PET/CT in patients with local non-small cell lung carcinoma treated with single-fraction carbon-ion radiotherapy.局部非小细胞肺癌患者单次分割碳离子放疗前代谢肿瘤体积对[S-甲基-C]-L-蛋氨酸PET/CT的预后价值
Ann Nucl Med. 2025 Jun 30. doi: 10.1007/s12149-025-02067-y.
2
L-3-[F]-Fluoro-α-Methyl Tyrosine as a PET Tracer for Tumor Diagnosis: A Systematic Review from Mechanisms to Clinical Applications.L-3-[F]-氟-α-甲基酪氨酸作为肿瘤诊断的正电子发射断层显像（PET）示踪剂：从机制到临床应用的系统评价
Int J Mol Sci. 2025 Jun 18;26(12):5848. doi: 10.3390/ijms26125848.
3

本文引用的文献

1
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.IASLC 肺癌分期项目：第八版肺癌 TNM 分类中 TNM 分期分组修订的外部验证。
J Thorac Oncol. 2017 Jul;12(7):1109-1121. doi: 10.1016/j.jtho.2017.04.011. Epub 2017 Apr 28.
2
Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235.代谢肿瘤体积可预测在ACRIN 6668/RTOG 0235试验中接受治疗的III期非小细胞肺癌患者的总生存期和局部控制情况。
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):17-24. doi: 10.1007/s00259-016-3520-4. Epub 2016 Sep 19.
3
LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals.
LAT1特异性PET放射性示踪剂：一类新型癌症特异性放射性药物的研发与临床经验。
Theranostics. 2025 Jan 2;15(5):1864-1878. doi: 10.7150/thno.99490. eCollection 2025.
4
Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.新型计算生物学建模系统可准确预测早期乳腺癌新辅助治疗的反应。
Breast Cancer Res. 2023 May 10;25(1):54. doi: 10.1186/s13058-023-01654-z.
5
Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose.肺癌的正电子发射断层扫描成像：除F18氟脱氧葡萄糖之外的其他正电子发射断层扫描示踪剂概述。
Front Med (Lausanne). 2022 Oct 5;9:945602. doi: 10.3389/fmed.2022.945602. eCollection 2022.
6
The Study of Tumor Volume as a Prognostic Factor in T Staging System for Non-Small Cell Lung Cancer: An Exploratory Study.肿瘤体积作为非小细胞肺癌 T 分期系统预后因素的研究：一项探索性研究。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820980106. doi: 10.1177/1533033820980106.
7
Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy.原发性肿瘤的最大标准化摄取值（SUVmax_PT）以及两个最远的PET阳性淋巴结之间的水平距离可预测不可切除的III期非小细胞肺癌患者放化疗后的预后。
Transl Lung Cancer Res. 2020 Jun;9(3):541-548. doi: 10.21037/tlcr.2020.04.04.
8
Tumor volume is more reliable to predict nodal metastasis in non-small cell lung cancer of 3.0 cm or less in the greatest tumor diameter.肿瘤体积对于预测最大肿瘤直径为3.0厘米或更小的非小细胞肺癌的淋巴结转移更为可靠。
World J Surg Oncol. 2020 Jul 15;18(1):168. doi: 10.1186/s12957-020-01946-0.
9
Development and External Validation of a Nomogram for Predicting Survival in Patients With Stage IA Non-small Cell Lung Cancer ≤2 cm Undergoing Sublobectomy.预测接受亚肺叶切除术的直径≤2 cm的IA期非小细胞肺癌患者生存情况的列线图的开发与外部验证
Front Oncol. 2019 Dec 11;9:1385. doi: 10.3389/fonc.2019.01385. eCollection 2019.
Lung Cancer Staging and Prognosis.
肺癌分期与预后
Cancer Treat Res. 2016;170:47-75. doi: 10.1007/978-3-319-40389-2_3.
4
Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging.LAT1对3-氟-L-α-甲基酪氨酸的特异性转运解释了其在成像中对恶性肿瘤的特异性。
Cancer Sci. 2016 Mar;107(3):347-52. doi: 10.1111/cas.12878. Epub 2016 Feb 19.
5
State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET.正电子发射断层扫描（PET）在肿瘤治疗随访中的定量技术现状和最新进展
Front Med (Lausanne). 2015 Mar 23;2:18. doi: 10.3389/fmed.2015.00018. eCollection 2015.
6
Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.肿瘤内炎症过程对 18F-FDG 摄取的影响：口腔鳞状细胞癌 18F-氟-α-甲基酪氨酸 PET/CT 的病理对照研究。
J Nucl Med. 2015 Jan;56(1):16-21. doi: 10.2967/jnumed.114.144014. Epub 2014 Dec 4.
7
Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.（18）F-FDG PET 容积参数对非小细胞肺癌的预后价值：一项荟萃分析。
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):241-51. doi: 10.1007/s00259-014-2903-7. Epub 2014 Sep 6.
8
Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.治疗前代谢肿瘤体积可预测食管鳞状细胞癌患者的无病生存期和总生存期。
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2008-16. doi: 10.1007/s00259-014-2839-y. Epub 2014 Jul 19.
9
Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer.氟-18-α-甲基酪氨酸（FAMT）摄取在食管癌患者 PET 上的生物学意义。
Br J Cancer. 2014 Apr 15;110(8):1985-91. doi: 10.1038/bjc.2014.142. Epub 2014 Mar 25.
10
FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描代谢肿瘤体积和总病灶糖酵解预测晚期肺腺癌患者的预后。
J Cancer Res Clin Oncol. 2014 Jan;140(1):89-98. doi: 10.1007/s00432-013-1545-7. Epub 2013 Nov 6.